Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Targeted therapies, particularly monoclonal antibodies, have revolutionized cancer treatment.
• Understanding molecular pathways driving tumor growth is key to developing effective therapies.
• Breast cancer treatment has significantly benefited from advances in targeted therapy.

Purpose of the Study:

• To review key monoclonal antibodies used in breast cancer treatment.
• To highlight the mechanisms and applications of trastuzumab, pertuzumab, and bevacizumab.
• To discuss the current and potential roles of these targeted agents in managing breast cancer.

Main Methods:

• Review of scientific literature on monoclonal antibodies in breast cancer.
• Focus on recombinant humanized monoclonal antibodies with demonstrated clinical activity.
• Analysis of drugs targeting growth factor receptors and angiogenic pathways.

Main Results:

• Trastuzumab (anti-erbB2) is a standard treatment for erbB2-positive metastatic and adjuvant breast cancer.
• Pertuzumab, targeting a different erbB2 epitope, shows promise in early clinical evaluation for broader patient populations.
• Bevacizumab (anti-vascular endothelial growth factor-A) demonstrates antiangiogenic properties and promising results in metastatic breast cancer.

Conclusions:

• Monoclonal antibodies targeting growth factor receptors are crucial in modern breast cancer management.
• Trastuzumab, pertuzumab, and bevacizumab represent significant therapeutic options with distinct mechanisms of action.
• Continued research into targeted therapies promises further improvements in breast cancer outcomes.